Toll Free: 1-888-928-9744

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 428 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2016', provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
- The report reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics and enlists all their major and minor projects
- The report assesses Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 7 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Overview 8 Therapeutics Development 9 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics under Development by Companies 11 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes 18 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Products Glance 20 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Products under Development by Companies 24 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Products under Investigation by Universities/Institutes 33 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Companies Involved in Therapeutics Development 36 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Assessment 119 Drug Profiles 131 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Recent Pipeline Updates 337 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects 394 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products 402 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Product Development Milestones 403 Appendix 409
List of Tables
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2016 27 Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Comparative Analysis, H1 2016 28 Number of Products under Development by Companies, H1 2016 29 Number of Products under Development by Companies, H1 2016 (Contd..1) 30 Number of Products under Development by Companies, H1 2016 (Contd..2) 31 Number of Products under Development by Companies, H1 2016 (Contd..3) 32 Number of Products under Development by Companies, H1 2016 (Contd..4) 33 Number of Products under Development by Companies, H1 2016 (Contd..5) 34 Number of Products under Development by Companies, H1 2016 (Contd..6) 35 Number of Products under Investigation by Universities/Institutes, H1 2016 36 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 37 Comparative Analysis by Late Stage Development, H1 2016 38 Comparative Analysis by Clinical Stage Development, H1 2016 39 Comparative Analysis by Early Stage Development, H1 2016 40 Comparative Analysis by Unknown Stage Development, H1 2016 41 Products under Development by Companies, H1 2016 42 Products under Development by Companies, H1 2016 (Contd..1) 43 Products under Development by Companies, H1 2016 (Contd..2) 44 Products under Development by Companies, H1 2016 (Contd..3) 45 Products under Development by Companies, H1 2016 (Contd..4) 46 Products under Development by Companies, H1 2016 (Contd..5) 47 Products under Development by Companies, H1 2016 (Contd..6) 48 Products under Development by Companies, H1 2016 (Contd..7) 49 Products under Development by Companies, H1 2016 (Contd..8) 50 Products under Investigation by Universities/Institutes, H1 2016 51 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 52 Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 53 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Absynth Biologics Limited, H1 2016 54 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Actelion Ltd, H1 2016 55 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Adenium Biotech ApS, H1 2016 56 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AIMM Therapeutics B.V., H1 2016 57 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Alchemia Limited, H1 2016 58 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Allergan Plc, H1 2016 59 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AlphaMab Co., Ltd, H1 2016 60 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Alvogen Korea Co., Ltd., H1 2016 61 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AmpliPhi Biosciences Corporation, H1 2016 62 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AnGes MG, Inc., H1 2016 63 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aphios Corporation, H1 2016 64 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Arsanis Biosciences GmbH, H1 2016 65 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AstraZeneca Plc, H1 2016 66 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aurigene Discovery Technologies Limited, H1 2016 67 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bavarian Nordic A/S, H1 2016 68 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bharat Biotech International Limited, H1 2016 69 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by BioDiem Ltd, H1 2016 70 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by C3 Jian, Inc, H1 2016 71 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cellceutix Corporation, H1 2016 72 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cempra, Inc., H1 2016 73 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ContraFect Corporation, H1 2016 74 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CrystalGenomics, Inc., H1 2016 75 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CSA Biotechnologies LLC , H1 2016 76 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Debiopharm International SA , H1 2016 77 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by DesignMedix, Inc., H1 2016 78 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Destiny Pharma Limited, H1 2016 79 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Emergent BioSolutions Inc., H1 2016 80 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ensol Biosciences Inc., H1 2016 81 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Excelimmune, Inc., H1 2016 82 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Galapagos NV, H1 2016 83 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by GangaGen Inc., H1 2016 84 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Gero Corp, H1 2016 85 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helix BioMedix, Inc., H1 2016 86 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Hsiri Therapeutics, LLC, H1 2016 87 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2016 88 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Immupharma Plc, H1 2016 89 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by iNtRON Biotechnology Inc., H1 2016 90 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ioGenetics, Inc., H1 2016 91 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 92 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lascco SA, H1 2016 93 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by LegoChem Biosciences, Inc, H1 2016 94 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Madam Therapeutics B.V., H1 2016 95 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Melinta Therapeutics, Inc, H1 2016 96 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Merck & Co., Inc., H1 2016 97 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Microbiotix, Inc., H1 2016 98 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2016 99 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MorphoSys AG, H1 2016 100 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Motif Bio Plc, H1 2016 101 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nabriva Therapeutics AG, H1 2016 102 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NanoBio Corporation, H1 2016 103 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nemus Bioscience, Inc., H1 2016 104 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2016 105 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Novabiotics Limited, H1 2016 106 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovaDigm Therapeutics, Inc., H1 2016 107 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H1 2016 108 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Omnia Molecular Ltd., H1 2016 109 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Oragenics, Inc., H1 2016 110 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Pepscan Presto BV, H1 2016 111 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Pfizer Inc., H1 2016 112 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Phico Therapeutics Limited, H1 2016 113 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Procarta Biosystems Limited, H1 2016 114 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Recce Limited, H1 2016 115 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Redx Pharma Plc, H1 2016 116 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2016 117 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Savara Inc., H1 2016 118 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sealife PHARMA GMBH, H1 2016 119 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H1 2016 120 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Soligenix, Inc., H1 2016 121 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sorrento Therapeutics, Inc., H1 2016 122 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Taejoon Pharm Co., Ltd., H1 2016 123 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H1 2016 124 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Telephus Medical LLC, H1 2016 125 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 126 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TGV-Laboratories, H1 2016 127 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Theravance Biopharma, Inc., H1 2016 128 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Trellis Bioscience, Inc., H1 2016 129 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by United Therapeutics Corporation, H1 2016 130 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Valevia UK Limited, H1 2016 131 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by VLP Biotech, Inc., H1 2016 132 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Wintermute Biomedical LLC, H1 2016 133 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Wockhardt Limited, H1 2016 134 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by XBiotech USA, Inc., H1 2016 135 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016 136 Assessment by Monotherapy Products, H1 2016 137 Assessment by Combination Products, H1 2016 138 Number of Products by Stage and Target, H1 2016 140 Number of Products by Stage and Mechanism of Action, H1 2016 143 Number of Products by Stage and Route of Administration, H1 2016 146 Number of Products by Stage and Molecule Type, H1 2016 148 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics - Recent Pipeline Updates, H1 2016 355 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H1 2016 412 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..1), H1 2016 413 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..2), H1 2016 414 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..3), H1 2016 415 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..4), H1 2016 416 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..5), H1 2016 417 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..6), H1 2016 418 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects (Contd..7), H1 2016 419 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products, H1 2016 420


List of Figures
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2016 27 Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Comparative Analysis, H1 2016 28 Number of Products under Development by Companies, H1 2016 29 Number of Products under Investigation by Universities/Institutes, H1 2016 36 Comparative Analysis by Clinical Stage Development, H1 2016 39 Comparative Analysis by Early Stage Products, H1 2016 40 Assessment by Monotherapy Products, H1 2016 137 Assessment by Combination Products, H1 2016 138 Number of Products by Top 10 Targets, H1 2016 139 Number of Products by Stage and Top 10 Targets, H1 2016 139 Number of Products by Top 10 Mechanism of Actions, H1 2016 142 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 142 Number of Products by Top 10 Routes of Administration, H1 2016 145 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 145 Number of Products by Top 10 Molecule Types, H1 2016 147 Number of Products by Stage and Top 10 Molecule Types, H1 2016 147

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...

Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to mo

Read More...

U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposable

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...

Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecast

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify